title: Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.
abstract: The frequency of transmitted HIV drug resistance (HIVDR) was evaluated in the context of rapid scale-up of antiretroviral treatment in Thailand, Vietnam, Burkina Faso, Côte d'Ivoire, and Senegal by using an adaptation of the WHO generic protocol of the HIV Drug Resistance Threshold Survey (HIVDR-TS) for sample collection and classification. Resistance-associated mutations were interpreted using the 2009 WHO list for epidemiological surveys. We included 266 subjects from the five study sites. Of the 266 RT and PR sequences analyzed, two from Vietnam harbored virus with major drug resistance mutations (G190A in RT for one individual and M46I in PR for the second individual). Phylogenetic analysis revealed that CRF01_AE predominates (>90%) in Thailand and Vietnam. CRF02 (>65%) cocirculates with other HIV-1 variants in Senegal and Côte d'Ivoire. The prevalence of HIVDRM is scored as low (< or = 5%) in all the five sites for the three drug classes analyzed. A continuous population survey for HIVDRM will provide a rational basis for maintaining or changing the current first line regimen in these countries.
authors.affiliation: UMR145, IRD and University of Montpellier 1, Montpellier, France. ahidjo.ayouba@mpl.ird.fr
authors.forename: Ahidjo
authors.initials: A
authors.lastname: Ayouba
authors.forename: Truong T X
authors.initials: TT
authors.lastname: Lien
authors.forename: Janin
authors.initials: J
authors.lastname: Nouhin
authors.forename: Laurence
authors.initials: L
authors.lastname: Vergne
authors.forename: Avelin Fobang
authors.initials: AF
authors.lastname: Aghokeng
authors.forename: Nicole
authors.initials: N
authors.lastname: Ngo-Giang-Huong
authors.forename: Halimatou
authors.initials: H
authors.lastname: Diop
authors.forename: Coumba Touré
authors.initials: CT
authors.lastname: Kane
authors.forename: Diane
authors.initials: D
authors.lastname: Valéa
authors.forename: François
authors.initials: F
authors.lastname: Rouet
authors.forename: Dominique
authors.initials: D
authors.lastname: Joulia-Ekaza
authors.forename: Thomas D'Aquin
authors.initials: TD
authors.lastname: Toni
authors.forename: Eric
authors.initials: E
authors.lastname: Nerrienet
authors.forename: Eitel Mpoudi
authors.initials: EM
authors.lastname: Ngole
authors.forename: Eric
authors.initials: E
authors.lastname: Delaporte
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
authors.forename: Martine
authors.initials: M
authors.lastname: Peeters
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Chaix
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002050:Burkina Faso / Q000453:epidemiology; D007560:Cote d'Ivoire / Q000453:epidemiology; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D016333:HIV Protease / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D010802:Phylogeny; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D015995:Prevalence; D012675:Senegal / Q000453:epidemiology; D017422:Sequence Analysis, DNA; D013785:Thailand / Q000453:epidemiology; D014744:Vietnam / Q000453:epidemiology; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase; D016333:HIV Protease